{"entity":{"id":"asp2138","kind":"drug","name":"ASP2138","aka":[],"tldr":"ASP2138 is an experimental bispecific antibody from Astellas Pharma Global Development in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2 and CD3.","summary":"ASP2138 is a bispecific antibody developed by Astellas Pharma Global Development. Its targets are Claudin 18.2 and CD3 (the sponsor names CLDN18.2 x CD3). The sponsor states: Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673887 (A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer), in gastric & gastro-oesophageal junction cancer. The largest, NCT07673887, plans to enrol 570 participants with primary completion expected 2031-02-28. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ASP2138","url":"https://clinicaltrials.gov/search?intr=ASP2138"},{"label":"Sponsor pipeline page","url":"https://newsroom.astellas.com/2026-08-25-astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":["cldn18-2","cd3"],"drugs":[],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07673887"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"bispecific antibody","mechanism":"Binds CLDN18.2 (claudin 18.2) on tumour cells and CD3 on T cells, bringing T cells into proximity with CLDN18.2-expressing tumour cells to activate an anti-tumour T-cell response; administered subcutaneously.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/asp2138/","neighbours":{"cancer":[{"id":"gastric-cldn18-2-positive","kind":"cancer","name":"Claudin 18.2-positive gastric cancer","route":"/cancers/gastric-cldn18-2-positive/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}],"trial":[{"id":"nct07673887","kind":"trial","name":"A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer","route":"/trials/nct07673887/"}]}}